Table 2 Best overall response assessed by IRC

From: The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial

 

KN046 3 mg/kg Q2W + nab-paclitaxel (n = 15)

KN046 5 mg/kg Q2W + nab-paclitaxel (n = 10)

Totala (n = 25)

Best overall response, n (%)

Complete response, CR

1 (6.7%)

0

1 (4.0%)

Partial response, PR

8 (53.3%)

2 (20.0%)

10 (40.0%)

Stable disease, SD

6 (40.0%)

7 (70.0%)

13 (52.0%)

Progressive disease, PD

0

1 (10.0%)

1 (4.0%)

Objective response rate, ORR (95% CI)

[CR + PR]

60.0%

(32.3–83.7%)

20.0%

(2.5–55.6%)

44.0%

(24.4–65.1%)

Disease control rate, DCR (95% CI)

[CR + PR + SD]

100.0%

(78.2–100.0%)

90.0%

(55.5–99.8%)

96.0%

(79.7–99.9%)

Clinical benefit rate, CBR (95% CI)

[CR + PR + SD ≥ 24 weeks]

60.0%

(32.3–83.7%)

40.0%

(12.2–73.8%)

52.0%

(31.3–72.2%)

Median DoR

Not reached

Not reached

Not reached

  1. aTwo patients withdrew from the trial before the first tumor assessment and were excluded from the evaluable population.
  2. IRC independent review committee.
Back to article page